Polyacrylamide Insulin Formulations for Monomer Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rapid-acting insulin formulations fail to mimic the ultra-rapid response of endogenous insulin secretion due to the instability of insulin monomers, leading to delayed onset and prolonged action, which is a limitation in commercial use and automated insulin delivery systems.
Innovation Solution
The use of polyacrylamide-based copolymers as stabilizing excipients in insulin formulations, preventing aggregation and maintaining insulin activity by incorporating water-soluble carrier and functional dopant monomers, thereby stabilizing insulin in a monomeric or lower-order association state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If zinc-stabilized hexamers are used in insulin formulations, then insulin stability and shelf-life are improved, but the onset of action is delayed due to slow dissociation in the subcutaneous space
Solution Approach 1:
The patent changes the chemical parameters of the formulation by incorporating specific excipients (polyols, amino acids, or peptides) that modify the dissociation kinetics of insulin hexamers. These excipients create a chemical environment that accelerates the dissociation process while maintaining formulation stability, thereby reducing the onset delay without compromising shelf-life.
Solution Approach 2:
The patent introduces intermediary substances (excipients) that mediate between the stable hexamer form and the active monomer form. These excipients facilitate the transition from hexamer to monomer by interacting with the insulin molecules, promoting dissociation while maintaining overall formulation stability during storage.
2Loss of time
If insulin monomers are used to achieve fastest absorption, then onset of action is improved, but formulation stability deteriorates due to high instability of insulin monomers
Solution Approach 1:
The patent creates a composite formulation system combining insulin monomers with stabilizing excipients. This composite approach allows the formulation to exhibit both rapid onset (from monomer) and improved stability (from excipient interaction), achieving a synergistic effect that resolves the contradiction between speed and stability.
Solution Approach 2:
The patent uses excipients as intermediary protective agents that shield insulin monomers from aggregation and degradation. These intermediaries maintain the monomeric form during storage and administration, preventing the instability issues that would otherwise occur with pure monomer formulations.
3Stability of the object's composition
If hexamers are used to maintain insulin stability, then shelf-life is improved, but duration of action is prolonged due to slow dissociation rate
Solution Approach 1:
The patent modifies the dissociation rate parameter by incorporating excipients that specifically accelerate the hexamer-to-monomer transition. This creates a formulation that maintains stability during storage (high shelf-life) but exhibits accelerated dissociation upon administration (reduced duration of action), resolving the contradiction between these two parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyacrylamide-based copolymers enhance insulin stability, allowing for faster absorption and reduced duration of action, thereby improving the efficacy of insulin formulations.
Implementation Method 1
the polyacrylamide-based copolymers of this disclosure can confer a substantial stability benefit to compositions including insulin or an analog thereof, by precluding adsorption of the insulin to the interfaces of the composition, thereby preventing undesirable aggregation events
Data Source
AI summary
The present disclosure provides compositions including a polyacrylamide-based copolymer, one or more preservatives, and insulin or an analog thereof. Also provided are methods of using the insulin compositions, including methods of administering the compositions to a human subject in need thereof.